Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment

Recently new drugs targeting androgen-dependent axis have been approved for the treatment of castration-resistant prostate cancer (CRPC) - Zytiga and Xtandi (formerly MDV3100), several other candidates (for example, ARN-509) are in early phases of clinical trials. However despite significant improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivachtchenko, Alexandre V., Mitkin, Oleg D., Kudan, Elizaveta V., Rjahovsky, Alexey A., Vorobiev, Anton A., Trifelenkov, Andrey S., Shevkun, Natalia A., Proskurina, Oxana V., Kravchenko, Dmitry V., Karapetian, Ruben N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768/
https://www.ncbi.nlm.nih.gov/pubmed/24494031
http://dx.doi.org/10.7150/jca.7773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768/
https://www.ncbi.nlm.nih.gov/pubmed/24494031
http://dx.doi.org/10.7150/jca.7773

Ejemplares similares